Jamison Private Wealth Management Inc. Reduces Position in Sanofi (NASDAQ:SNY)

Jamison Private Wealth Management Inc. trimmed its stake in Sanofi (NASDAQ:SNYFree Report) by 5.1% in the 4th quarter, HoldingsChannel reports. The firm owned 27,917 shares of the company’s stock after selling 1,488 shares during the period. Jamison Private Wealth Management Inc.’s holdings in Sanofi were worth $1,346,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. Franklin Resources Inc. increased its position in Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after buying an additional 395,744 shares in the last quarter. Natixis Advisors LLC increased its holdings in Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after acquiring an additional 114,133 shares in the last quarter. Raymond James & Associates raised its stake in Sanofi by 4.8% during the 3rd quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock worth $162,479,000 after acquiring an additional 129,472 shares during the period. JPMorgan Chase & Co. lifted its holdings in Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Finally, Brandes Investment Partners LP boosted its position in shares of Sanofi by 8.4% in the second quarter. Brandes Investment Partners LP now owns 2,122,748 shares of the company’s stock worth $102,706,000 after purchasing an additional 165,256 shares during the period. 14.04% of the stock is owned by institutional investors.

Sanofi Stock Performance

NASDAQ:SNY opened at $52.48 on Friday. The stock has a 50-day moving average price of $48.70 and a 200 day moving average price of $52.19. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The stock has a market capitalization of $133.19 billion, a P/E ratio of 26.78, a P/E/G ratio of 1.19 and a beta of 0.57.

Sanofi (NASDAQ:SNYGet Free Report) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the business posted $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. Equities research analysts forecast that Sanofi will post 3.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Read Our Latest Stock Report on SNY

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Read More

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.